Opportunity Information: Apply for RFA DA 10 010
Apply for RFA DA 10 010
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Exploring Epigenomic Processes and Non Coding RNAs in HIV/AIDS (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Sep 3, 2009 and posted on Sep 3, 2009.
- Applicants must submit their applications by Dec 23, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,500,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $750,000.00 in funding.
- Eligible applicants include: Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Private institutions of higher education Independent school districts Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) City or township governments Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Special district governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity, titled "Exploring Epigenomic Processes and Non Coding RNAs in HIV/AIDS (R01)" (Funding Opportunity Number RFA-DA-10-010), was issued by the National Institute on Drug Abuse (NIDA) within the National Institutes of Health (NIH). Its central goal is to deepen scientific understanding of how epigenomic regulation and non-coding RNAs influence HIV infection and HIV-related disease processes, specifically in the context of substance use or substance abuse. The program is framed around the idea that drug exposure can alter gene regulation without changing DNA sequence, and that these changes may affect HIV replication, latency, immune dysfunction, neurological outcomes, and overall pathogenesis. In addition to supporting studies that answer existing questions, the announcement explicitly encourages innovative, boundary-pushing projects that open up new directions or introduce new methods and approaches to ongoing lines of research.
The FOA uses the NIH Research Project Grant (R01) mechanism, which typically supports more mature, hypothesis-driven projects with a stronger base of preliminary data and a clearer plan for producing substantial outcomes. This R01 announcement is paired with a companion funding opportunity (RFA-DA-10-011) using the R21 Exploratory/Developmental mechanism, which is generally intended for earlier-stage, higher-risk ideas. Both announcements share the same scientific scope, and together they reflect a coordinated effort to grow a research area that sits at the intersection of HIV/AIDS biology, addiction science, and epigenomics. A notable emphasis is placed on building newly formed collaborations, with the intention of bringing together investigators who may have deep expertise in one domain (for example, HIV latency or substance use neuroscience) but need partners with advanced epigenomics or non-coding RNA capabilities, or vice versa.
In terms of funding, NIH set aside an estimated total of $2.5 million to support awards across both the R01 and R21 announcements combined. For the R01 portion specifically, the anticipated number of awards was relatively small, with an estimate of about 2 to 4 R01 grants funded, alongside roughly 4 to 6 R21 grants under the companion FOA. The listed award ceiling for this opportunity is $750,000, which signals that projects could be sizable but would still need to be carefully scoped and justified within NIH budget norms and expectations for an R01.
Eligibility is broad and includes a wide range of organizational types. Eligible applicants include public and private institutions of higher education, nonprofit organizations (both with and without 501(c)(3) status), for-profit organizations (including but not limited to small businesses), state and local governments (including county, city/township, special district governments), independent school districts, public housing authorities, and tribal governments and tribal organizations (including federally recognized tribal governments and other tribal entities). The FOA also lists additional eligible groups such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, faith-based and community-based organizations, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). There is no cost sharing or matching requirement, meaning applicants are not required to contribute non-federal funds as a condition of receiving an award.
From an administrative standpoint, this opportunity is categorized as discretionary funding and uses the grant funding instrument type, with the activity category listed under education/health and the CFDA number 93.279 (Drug Abuse and Addiction Research Programs). The FOA was posted on September 3, 2009, with an original and current closing date of December 23, 2009, and it was later archived on January 23, 2010. The full announcement was made available through the NIH grants website, and the contact pathway provided is through the NIH Office of Extramural Research (OER) web support for access or linking issues.
Overall, the announcement is best understood as a targeted research push: it aims to catalyze rigorous R01-level projects that explain and potentially leverage epigenomic mechanisms and non-coding RNA biology to clarify how substance use modifies HIV disease trajectories. Just as importantly, it tries to shape the research community by encouraging cross-disciplinary teams, since the most impactful work in this area often requires combining HIV virology and immunology, addiction biology, and high-dimensional epigenomic profiling and analysis into a single integrated study design.
Frequently Asked Questions (FAQs)
What is the title and funding opportunity number for this grant?
The funding opportunity is titled "Exploring Epigenomic Processes and Non Coding RNAs in HIV/AIDS (R01)" and the Funding Opportunity Number is RFA-DA-10-010.
Which agency and institute issued this opportunity?
This opportunity was issued by the National Institute on Drug Abuse (NIDA) within the National Institutes of Health (NIH).
What is the main scientific focus of this FOA?
The FOA aims to deepen scientific understanding of how epigenomic regulation and non-coding RNAs influence HIV infection and HIV-related disease processes, specifically in the context of substance use or substance abuse.
How does substance use relate to the research goals described in the announcement?
The program is built around the idea that drug exposure can alter gene regulation without changing the DNA sequence (epigenomic effects). These regulatory changes may affect HIV replication, latency, immune dysfunction, neurological outcomes, and overall HIV pathogenesis.
What types of HIV-related outcomes or processes are highlighted as relevant?
The FOA highlights HIV replication, HIV latency, immune dysfunction, neurological outcomes, and broader disease pathogenesis as areas where epigenomic regulation and non-coding RNAs may play important roles, particularly under conditions of substance use or substance abuse.
What kinds of projects does the FOA encourage?
In addition to studies addressing existing questions, the FOA explicitly encourages innovative, boundary-pushing projects that open up new research directions or introduce new methods and approaches to ongoing lines of research.
What grant mechanism is used for this opportunity?
This FOA uses the NIH Research Project Grant (R01) mechanism.
How is an R01 described in this announcement?
The announcement characterizes the R01 as typically supporting more mature, hypothesis-driven projects with a stronger base of preliminary data and a clearer plan for producing substantial outcomes.
Is there a companion funding opportunity related to this announcement?
Yes. This R01 FOA is paired with a companion FOA (RFA-DA-10-011) that uses the R21 Exploratory/Developmental mechanism.
How is the companion R21 mechanism described?
The R21 is described as generally intended for earlier-stage, higher-risk ideas. The R01 and R21 announcements share the same scientific scope.
What is the broader program intent across the R01 and R21 announcements?
Together, the R01 and R21 FOAs reflect a coordinated effort to grow a research area at the intersection of HIV/AIDS biology, addiction science, and epigenomics (including non-coding RNA biology).
Does the FOA emphasize collaboration?
Yes. A notable emphasis is placed on building newly formed collaborations, with the goal of bringing together investigators with complementary expertise (for example, HIV latency or substance use neuroscience combined with epigenomics or non-coding RNA capabilities).
How much funding did NIH set aside for awards across these announcements?
NIH set aside an estimated total of $2.5 million to support awards across both the R01 (RFA-DA-10-010) and the companion R21 (RFA-DA-10-011) announcements combined.
How many awards were anticipated for the R01 portion?
For the R01 portion specifically, the anticipated number of awards was relatively small, estimated at about 2 to 4 R01 grants.
How many awards were anticipated for the companion R21 portion?
The companion FOA anticipated roughly 4 to 6 R21 grants.
What is the listed award ceiling for this opportunity?
The listed award ceiling for this FOA is $750,000.
Does the FOA suggest anything about project size or scope given the award ceiling?
Yes. The $750,000 ceiling signals that projects could be sizable, but they would still need to be carefully scoped and justified within NIH budget norms and expectations for an R01.
Who is eligible to apply?
Eligibility is broad and includes many organization types, including public and private institutions of higher education, nonprofit organizations (with or without 501(c)(3) status), and for-profit organizations (including small businesses).
Are government entities eligible to apply?
Yes. Eligible applicants include state and local governments, including county governments, city or township governments, and special district governments.
Are school systems and housing authorities eligible to apply?
Yes. Independent school districts and public housing authorities are included among eligible applicants.
Are tribal governments and tribal organizations eligible?
Yes. The FOA includes federally recognized tribal governments and other tribal entities, as well as tribal organizations, among eligible applicants.
Are minority-serving institutions specifically listed as eligible?
Yes. The FOA lists Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), and Alaska Native and Native Hawaiian-serving institutions as eligible.
Are faith-based and community-based organizations eligible?
Yes. Faith-based and community-based organizations are explicitly listed among eligible applicants.
Are U.S. territories or regional organizations eligible?
Yes. U.S. territories or possessions and regional organizations are included in the eligibility list.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The FOA states that non-U.S. entities (foreign organizations) are eligible applicants.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement for this opportunity.
What type of funding is this categorized as?
This opportunity is categorized as discretionary funding and uses the grant funding instrument type.
What is the activity category and CFDA number associated with this FOA?
The activity category is listed under education/health, and the CFDA number is 93.279 (Drug Abuse and Addiction Research Programs).
When was the FOA posted, and what were the closing dates?
The FOA was posted on September 3, 2009. The original and current closing date was December 23, 2009.
Is this funding opportunity still active?
No. The FOA was later archived on January 23, 2010.
Where was the full announcement made available?
The full announcement was made available through the NIH grants website.
Who is the contact for access or linking issues related to the announcement?
The contact pathway provided is through the NIH Office of Extramural Research (OER) web support for access or linking issues.
How should this FOA be understood at a high level?
It is a targeted research push intended to catalyze rigorous R01-level projects that clarify how epigenomic mechanisms and non-coding RNA biology shape HIV disease trajectories in the context of substance use, while also encouraging cross-disciplinary research teams.
What disciplines or expertise areas does the FOA imply may need to be integrated?
The FOA points to a need for integrated study designs that can combine HIV virology and immunology, addiction biology, and high-dimensional epigenomic profiling and analysis, often through cross-disciplinary collaborations.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Exploring Epigenomic Processes and Non Coding RNAs in HIV/AIDS (R21)
Previous opportunity: Specialized Cooperative Centers Program in Reproduction and Infertility Research (U54)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 10 010
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 10 010) also looked into and applied for these:
| Funding Opportunity |
|---|
| Exploring Epigenomic Processes and Non Coding RNAs in HIV/AIDS (R21) Apply for RFA DA 10 011 Funding Number: RFA DA 10 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Targeted Library Synthesis and Screening at Novel Targets for Potential Drug Addiction Treatments and Research Tools (R21/R33) Apply for RFA DA 10 005 Funding Number: RFA DA 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) (R01) Apply for RFA GM 10 009 Funding Number: RFA GM 10 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Developing Research Capacity in Africa for Studies on HIV Associated Malignancies (D43) Apply for RFA CA 09 016 Funding Number: RFA CA 09 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Medications Development for Cannabis Related Disorders (R01) Apply for RFA DA 10 016 Funding Number: RFA DA 10 016 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011 and 2012 (P50) Apply for PAR 10 003 Funding Number: PAR 10 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Discovery for Nervous System Disorders (R21) Apply for PAR 10 002 Funding Number: PAR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Drug Discovery for Nervous System Disorders (R01) Apply for PAR 10 001 Funding Number: PAR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Community Networks Program (CNP) Centers for Reducing Cancer Disparities through Outreach, Research and Training (U54) Apply for RFA CA 09 032 Funding Number: RFA CA 09 032 Agency: National Institutes of Health Category: Education Health Funding Amount: $900,000 |
| Pathway to Independence Award in Cancer Nanotechnology Research (K99/R00) Apply for RFA CA 09 015 Funding Number: RFA CA 09 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Nanotechnology Training Centers (CNTCs)(R25) Apply for RFA CA 09 014 Funding Number: RFA CA 09 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $400,000 |
| Behavioral and Integrative Treatment Development Program (R01) Apply for PA 10 012 Funding Number: PA 10 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R03) Apply for PA 10 011 Funding Number: PA 10 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R34) Apply for PA 10 013 Funding Number: PA 10 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33) Apply for RFA CA 10 002 Funding Number: RFA CA 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Application and Early Stage Development of Emerging Technologies in Cancer Research (R21) Apply for RFA CA 10 003 Funding Number: RFA CA 10 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Innovative Technology Development for Cancer Research (R21) Apply for RFA CA 10 005 Funding Number: RFA CA 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Validation and Advanced Development of Emerging Technologies for Cancer Research (R33) Apply for RFA CA 10 004 Funding Number: RFA CA 10 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Innovative and Early Stage Development of Emerging Technologies in Biospecimen Science (R21) Apply for RFA CA 10 001 Funding Number: RFA CA 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Accelerating the Pace of Drug Abuse Research Using Existing Epidemiology, Prevention, and Treatment Research Data (R01) Apply for PAR 10 018 Funding Number: PAR 10 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 10 010", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.